EP2398484A4 - Inhibition de voies multiples d'activation cellulaire - Google Patents

Inhibition de voies multiples d'activation cellulaire

Info

Publication number
EP2398484A4
EP2398484A4 EP10743341.9A EP10743341A EP2398484A4 EP 2398484 A4 EP2398484 A4 EP 2398484A4 EP 10743341 A EP10743341 A EP 10743341A EP 2398484 A4 EP2398484 A4 EP 2398484A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
cell activation
multiple cell
activation pathways
pathways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10743341.9A
Other languages
German (de)
English (en)
Other versions
EP2398484A1 (fr
Inventor
Michael Valentine Agrez
Douglas Dorahy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
InterK Peptide Therapeutics Ltd
Original Assignee
Inter K Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009900762A external-priority patent/AU2009900762A0/en
Application filed by Inter K Pty Ltd filed Critical Inter K Pty Ltd
Publication of EP2398484A1 publication Critical patent/EP2398484A1/fr
Publication of EP2398484A4 publication Critical patent/EP2398484A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP10743341.9A 2009-02-23 2010-02-23 Inhibition de voies multiples d'activation cellulaire Withdrawn EP2398484A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2009900762A AU2009900762A0 (en) 2009-02-23 Inhibition of cancer cell growth
AU2009900764A AU2009900764A0 (en) 2009-02-23 Treatment of cancer
AU2009902829A AU2009902829A0 (en) 2009-06-19 Anti-cancer agents and use of same
AU2009902871A AU2009902871A0 (en) 2009-06-22 Anti-cancer agents and use of same II
AU2009903938A AU2009903938A0 (en) 2009-08-20 Inhibition of multiple cell activation pathways
PCT/AU2010/000203 WO2010094085A1 (fr) 2009-02-23 2010-02-23 Inhibition de voies multiples d'activation cellulaire

Publications (2)

Publication Number Publication Date
EP2398484A1 EP2398484A1 (fr) 2011-12-28
EP2398484A4 true EP2398484A4 (fr) 2013-07-10

Family

ID=42633365

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10743341.9A Withdrawn EP2398484A4 (fr) 2009-02-23 2010-02-23 Inhibition de voies multiples d'activation cellulaire

Country Status (4)

Country Link
EP (1) EP2398484A4 (fr)
JP (1) JP2012518602A (fr)
AU (1) AU2010215086A1 (fr)
WO (1) WO2010094085A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013110120A1 (fr) 2012-01-24 2013-08-01 Inter-K Pty Limited Agents peptidiques utilisés en thérapie anticancéreuse
KR20210021984A (ko) * 2018-05-15 2021-03-02 인터크 펩타이드 테라퓨틱스 리미티드 펩타이드 활성화 제제
US20210380639A1 (en) * 2018-05-15 2021-12-09 Interk Peptide Therapeutics Limited Activating Agents
CA3120624A1 (fr) * 2018-11-30 2020-06-04 Interk Peptide Therapeutics Limited Polypeptides et methodes pour soulager les affections cutanees
WO2023019323A1 (fr) * 2021-08-20 2023-02-23 Interk Peptide Therapeutics Limited Compositions et procédés de traitement de l'auto-immunité, comprenant l'auto-immunité associée au cancer et à la thérapie du cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000677A1 (fr) * 1999-06-28 2001-01-04 The University Of Newcastle Research Associates Limited Procede servant a moduler une activite cellulaire provoquee par integrine et agents de modulation utiles
WO2002051993A1 (fr) * 2000-12-22 2002-07-04 The University Of Newcastle Research Associates Limited Domaine de liaison a l'integrine de la map kinase
WO2005037308A1 (fr) * 2003-10-17 2005-04-28 Inter-K Pty Limited Procedes et agents pour le traitement du cancer
WO2009103127A1 (fr) * 2008-02-22 2009-08-27 Inter-K Pty Limited Peptides thérapeutiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
AUPR330201A0 (en) 2001-02-23 2001-03-22 University Of Sydney, The Metal complexes and therapeutic uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000677A1 (fr) * 1999-06-28 2001-01-04 The University Of Newcastle Research Associates Limited Procede servant a moduler une activite cellulaire provoquee par integrine et agents de modulation utiles
WO2002051993A1 (fr) * 2000-12-22 2002-07-04 The University Of Newcastle Research Associates Limited Domaine de liaison a l'integrine de la map kinase
WO2005037308A1 (fr) * 2003-10-17 2005-04-28 Inter-K Pty Limited Procedes et agents pour le traitement du cancer
WO2009103127A1 (fr) * 2008-02-22 2009-08-27 Inter-K Pty Limited Peptides thérapeutiques

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHENG J Q ET AL: "The Akt/PKB pathway: Molecular target for cancer drug discovery", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 24, no. 50, 14 November 2005 (2005-11-14), pages 7482 - 7492, XP008104381, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1209088 *
CLARK EDWIN A ET AL: "Integrins and signal transduction pathways: The road taken", SCIENCE (WASHINGTON D C), vol. 268, no. 5208, 1995, pages 233 - 239, XP002697789, ISSN: 0036-8075 *
GIANCOTTI F G ET AL: "Integrin-mediated adhesion and signaling in tumorigenesis", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1198, no. 1, 27 May 1994 (1994-05-27), pages 47 - 64, XP023789795, ISSN: 0304-419X, [retrieved on 19940527], DOI: 10.1016/0304-419X(94)90005-1 *
LEE CAMERON C ET AL: "Designing dendrimers for biological applications", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 12, 1 December 2005 (2005-12-01), pages 1517 - 1526, XP002496723, ISSN: 1087-0156, DOI: 10.1038/NBT1171 *
LEE, C.C. ET AL.: "Designing Dendrimers for Biological Applications", NATURE BIOTECHNOLOGY., vol. 23, no. 12, 2005, pages 1517 - 1526, XP002697788 *
See also references of WO2010094085A1 *
V. THAMILSELVAN ET AL: "FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway", THE FASEB JOURNAL, vol. 21, no. 8, 21 February 2007 (2007-02-21), pages 1730 - 1741, XP055064346, ISSN: 0892-6638, DOI: 10.1096/fj.06-6545com *

Also Published As

Publication number Publication date
JP2012518602A (ja) 2012-08-16
EP2398484A1 (fr) 2011-12-28
AU2010215086A1 (en) 2011-09-08
WO2010094085A1 (fr) 2010-08-26

Similar Documents

Publication Publication Date Title
HK1249547A1 (zh) 鹽藻糖基化欠缺細胞
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
HK1170258A1 (en) Expansion of nk cells nk
EP2580352A4 (fr) Caractérisation de voies de cellules
EP2497529A4 (fr) Électro-stimulateur
SG10201401643PA (en) Methods for assessing cytotoxicity of single cells
EP2437871A4 (fr) Carafe équipée d'un filtre à eau
ZA201008641B (en) Crystalline modifications of prothioconazole
GB2473273B (en) Urinal insert
EP2398484A4 (fr) Inhibition de voies multiples d'activation cellulaire
EP2296704A4 (fr) Mécanisme d'action d'un agent biologique dérivé d'une cellule primaire
GB0920775D0 (en) Cells
EP2488164A4 (fr) Libération d'agents par des cellules
GB201015579D0 (en) Provision of electrical energy
AU2009903938A0 (en) Inhibition of multiple cell activation pathways
HK1157387A1 (en) Use of hsa-producing cells
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
TWM386109U (en) Improved structure of water dispenser
GB0914739D0 (en) Enzyme inhibition
GB0914742D0 (en) Enzyme inhibition
PT2430214T (pt) Ativação de cátodo
GB201014190D0 (en) Enzyme inhibition
GB201014183D0 (en) Enzyme inhibition
TWM374127U (en) Structure of three-string Huqin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/10 20060101AFI20130529BHEP

Ipc: A61K 38/17 20060101ALI20130529BHEP

Ipc: A61P 35/00 20060101ALI20130529BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130611

17Q First examination report despatched

Effective date: 20150930

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160412